Drug Profile
Recombinant epidermal growth factor biosimilar - USV
Alternative Names: Epidermal growth factor biosimilar - USVLatest Information Update: 28 Jun 2019
Price :
$50
*
At a glance
- Originator USV
- Class Antiulcers; Growth factors
- Mechanism of Action Epidermal growth factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetic foot ulcer; Wounds
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for research development in Diabetic-foot-ulcer in India
- 28 Jun 2019 No recent reports of development identified for research development in Wounds in India
- 22 May 2015 Early research in Diabetic foot ulcer in India (unspecified route) (USV product pipeline, May 2015)